Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Repeated High-Dose MPA Therapy in Recurrent Early-Stage Endometrial Cancer or Atypical Endometrial Hyperplasia
KCT0009864Phase 2Not yet recruiting
- Sponsor
- Masan Samsung Medical Center
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of medroxyprogesterone acetate in Endometrial intraepithelial neoplasia (EIN), endometrial carcinoma (EC), sponsored by Masan Samsung Medical Center. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
medroxyprogesterone acetate
03
Conditions
Endometrial intraepithelial neoplasia (EIN)endometrial carcinoma (EC)
Beyond the preview
Go deeper on KCT0009864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009864.